Literature DB >> 27103489

Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.

Tim R Cressey1, Ram Yogev2, Andrew Wiznia3, Rohan Hazra4, Patrick Jean-Philippe5, Bobbie Graham6, Amy Gonzalez6, Paula Britto7, Vincent J Carey7, Courtney V Fletcher8, Edward P Acosta9.   

Abstract

Data on the combination of darunavir/ritonavir and etravirine both given twice daily in adolescents/young adults are lacking. In this study, we assessed the pharmacokinetics of darunavir/ritonavir 600/100 mg with etravirine 200 mg twice daily in 36 treatment-experienced human immunodeficiency virus-infected adolescents and young adults and found that exposures were comparable to those reported in adults.
© The Author 2017. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antiretrovirals; darunavir; etravirine; pediatrics; ritonavir

Mesh：

Substances：

Year:  2017        PMID： 27103489      PMCID： PMC5907875          DOI： 10.1093/jpids/piw017

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   3.164


  7 in total

1.  Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.

Authors:  Marta Boffito; Alan Winston; Akil Jackson; Carl Fletcher; Anton Pozniak; Mark Nelson; Graeme Moyle; Izabela Tolowinska; Richard Hoetelmans; Diego Miralles; Brian Gazzard
Journal:  AIDS       Date:  2007-07-11       Impact factor: 4.177

2.  Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.

Authors:  T N Kakuda; J R Wade; E Snoeck; P Vis; M Schöller-Gyüre; M P Peeters; C Corbett; S Nijs; J Vingerhoets; L Leopold; G De Smedt; B J Woodfall; R M W Hoetelmans
Journal:  Clin Pharmacol Ther       Date:  2010-09-29       Impact factor: 6.875

3.  Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.

Authors:  Gautam Baheti; Jennifer R King; Edward P Acosta; Courtney V Fletcher
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

4.  Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.

Authors:  Kajal B Larson; Tim R Cressey; Ram Yogev; Andrew Wiznia; Rohan Hazra; Patrick Jean-Philippe; Bobbie Graham; Amy Gonzalez; Paula Britto; Vincent J Carey; Edward P Acosta
Journal:  J Pediatric Infect Dis Soc       Date:  2015-01-28       Impact factor: 3.164

5.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

Authors:  Adriano Lazzarin; Thomas Campbell; Bonaventura Clotet; Margaret Johnson; Christine Katlama; Arend Moll; William Towner; Benoit Trottier; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Benny Baeten; Greet Beets; Rekha Sinha; Brian Woodfall
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

6.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

Authors:  José Valdez Madruga; Pedro Cahn; Beatriz Grinsztejn; Richard Haubrich; Jacob Lalezari; Anthony Mills; Gilles Pialoux; Timothy Wilkin; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Lorant Leopold; Roberta Trefiglio; Brian Woodfall
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

7.  Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.

Authors:  Stéphane Blanche; Rosa Bologna; Pedro Cahn; Sorin Rugina; Patricia Flynn; Claudia Fortuny; Peter Vis; Vanitha Sekar; Ben van Baelen; Inge Dierynck; Sabrina Spinosa-Guzman
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.